✉ Email this page to a colleague
« Back to Dashboard
Veliparib is an investigational drug.
There have been 96 clinical trials for Veliparib. The most recent clinical trial was a Phase 3 trial, which was initiated on April 10th 2014.
The most common disease conditions in clinical trials are Carcinoma, Breast Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), AbbVie, and AbbVie (prior sponsor, Abbott).
There are three hundred and fifty-five US patents protecting this investigational drug and seven international patents.
Recent Clinical Trials for Veliparib
|A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer||AbbVie||Phase 1|
|Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)||AHS Cancer Control Alberta||Phase 2|
|Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer||Fudan University||Phase 2|
Top disease conditions for Veliparib
Top clinical trial sponsors for Veliparib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Veliparib||See Plans and Pricing||Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines||Signal Pharmaceuticals, LLC (San Diego, CA)||See Plans and Pricing|
|Veliparib||See Plans and Pricing||Remote loading of sparingly water-soluble drugs into lipid vesicles||ZONEONE PHARMA, INC. (San Francisco, CA)||See Plans and Pricing|
|Veliparib||See Plans and Pricing||Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators||BEIGENE, LTD. (Grand Cayman, KY)||See Plans and Pricing|
|Veliparib||See Plans and Pricing||Compounds and compositions as inhibitors of MEK||Novartis AG (Basel, CH)||See Plans and Pricing|
|Veliparib||See Plans and Pricing||Bridged bicyclic nucleosides||MIRAGEN THERAPEUTICS, INC. (Boulder, CO)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Veliparib||European Patent Office||EP3131552||2034-04-16||See Plans and Pricing|
|Veliparib||Spain||ES2823756||2034-04-16||See Plans and Pricing|
|Veliparib||Japan||JP2017514806||2034-04-16||See Plans and Pricing|
|Veliparib||Japan||JP2019070012||2034-04-16||See Plans and Pricing|
|Veliparib||Japan||JP2021059548||2034-04-16||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|